Drug boosts treatment for blood cancer myeloma relapse patients

Professor Chng Wee Joo, director of the National University Cancer Institute, Singapore, and Madam Oh Hwee Hong, who is taking part in a trial for the myeloma drug carfilozomib.
Professor Chng Wee Joo, director of the National University Cancer Institute, Singapore, and Madam Oh Hwee Hong, who is taking part in a trial for the myeloma drug carfilozomib.ST PHOTO: DESMOND WEE

SINGAPORE - A drug, which aims to improve survival chances of relapsed myeloma patients, has been approved by the Health Sciences Authority (HSA).

Myeloma is an incurable blood cancer in the bone marrow or soft tissue. Symptoms include bone pain, kidney failure, and anaemia.

TO READ THE FULL ARTICLE

Thank you for reading The Straits Times

You have reached one of our Premium stories. To continue reading, get access now or log in if you are a subscriber.

What is Premium?